Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Ticker
Market factors today
Unlock the full LABT picture
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
LABT stock facts
| Ticker symbol | LABT |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.9M |
| CEO | Kelvin Cooper |
| Employees | 5 |
| Headquarters | University Park, FL, US |
| IPO date | 2026-04-23 |
| Website | www.lakewoodamedex.com |
What you can see for LABT on Tickr
Live LABT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the LABT report.
Rankings
FAQ
What is the ticker symbol for Lakewood-Amedex Biotherapeutics, Inc.?
The ticker symbol for Lakewood-Amedex Biotherapeutics, Inc. is LABT, listed on the NASDAQ Global Market.
What is LABT?
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic…